
Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harboring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021. “As we strive to identify the oncogenic driver in more and more of our […]
Read more